PneumoIQ™ Enter

Learn more about pneumococcal disease with this informative interactive site.

This site is intended only for residents of the United States.

If you are a resident of a country other than the United States, please visit Wyeth Worldwide to find information about our offices around the globe.

Wyeth
Find out more information about all Wyeth products.

Prevnar®; Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein); The first pneumococcal conjugate vaccine
Help Protect Your Child. What you should know about vaccination. - This site is intended for U.S. residents only. Please scroll down to see Important Safety Information. Important Safety Information

Adobe Flash Player Required; Certain portions of the PREVNAR website require the latest version of the free Adobe Flash Player. Click on the button to the right to download the latest player. Get Adobe Flash Player

References

  1. Centers for Disease Control and Prevention. Vaccine preventable deaths and the global immunization vision and strategy, 2006–2015. MMWR. 2006;
    55:511-515.
  2. Data on File, Wyeth Pharmaceuticals
  3. Black S, Shinefield H, Fireman B, et al. Efficacy, safety, and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
  4. Prescribing Information for Prevnar®, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein). Wyeth Pharmaceuticals Inc.
  5. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46:1-24.
  6. Black S, Shinefield H. Issues and challenges: pneumococcal vaccination in pediatrics. Pediatr Ann. 1997;26:355-360.
  7. Fedson DS, Musher DM, Eskola J. Pneumococcal vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders Company; 1999:553-607.
  8. Syrogiannopoulos GA, Grivea IN, Katopodis GD, et al. Carriage of antibiotic-resistant Streptococcus pneumoniae in Greek infants and toddlers. Eur J Clin Microbiol Infect Dis. 2000;19:288-293.
  9. Christenson B, Sylvan SPE, Noreen B. Carriage of multiresistant Streptococcus pneumoniae among children attending day-care centres in the Stockholm area. Scand J Infect Dis. 1997;29:555-558.
  10. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR [serial online]. 2000;49(RR-9): 1-38. Available at: http://www.cdc.gov/mmwr/PDF/RR/RR4909.pdf. Accessed June 15, 2007.
  11. Fireman B, Black S, Shinefield H, et al. The impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10-16.
  12. Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23:732-738.
  13. Black SB, Shinefeld HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21:810-815.
  14. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4):604-11.

Important Safety Information

Ask your child's health care provider about the risks and benefits of Prevnar® and if Prevnar® is right for your child.

In clinical studies, the most frequently reported adverse events included injection site reactions, fever (38ºC/100.4ºF), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevnar®. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevnar® does not protect 100% of children vaccinated. Immunization with Prevnar® does not substitute for routine diphtheria immunization.

Please see Prescribing Information.